ABSTRACT
Objective:To investigate the effects of survivin inhibitor YM155{1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-1H-naphtho[2,3-d] imidazolium bromide} on cell viability,apoptosis and Cysteinyl aspartate specific proteinase-3,Cysteinyl aspartate specific proteinase-8,Cysteinyl aspartate specific proteinase-9 of the thyroid carcinoma cell line B-CPAP in order to discuss mitochondrial mechanisms of apoptosis.Methods: B-CPAP cells were cultured in vitro and treated with YM155 at various concentrations(0,0.5,1,2,4,8 nmol/L)for 24,48 and 72h.The cell viability of B-CPAP cells were measured by CCK-8 assay.B-CPAP cells were randomly divided into 4 groups:B-CPAP cells were treated with YM155 at various concentrations(0,1,2 nmol/L)and 5 μmol/L Cisplatin(the positive control group)for 24 h.The effects of YM155 on B-CPAP cells apoptosis were evaluated by TUNEL and flow cytometry Annexin V-FITC/PI method.The expression level of Survivin and Caspase-3,Caspase-8 ,Caspase-9 were detected by Western blot analysis.Results: Compared with the 0 nmol/L group,YM155 significantly inhibited the cell viability of B-CPAP cells and induced their apoptosis (P<0.05 or P<0.01).Compared with the 0 nmol/L group,YM155 significantly reduced the expression level of Survivin and upregulated Caspase-3,Caspase-8 ,Caspase-9(P<0.05 or P<0.01).Conclusion: YM155 can inhibit the cell viability of B-CPAP cells and induce apoptosis,its possible mechanisms maybe related to upregulated expression level of Caspase-3,Caspase-8 and Caspase-9.
ABSTRACT
OBJECTIVE:To observe the effect of atorvastatin combined with methylprednisolone on the liver function of ne-phrotic syndrome patients. METHODS:The data of 93 patients with primary nephritic syndrome were retrospectively analyzed and divided into atorvastatin group,methylprednisolone group and combination group by different medication. Atorvastatin group was orally given atorvastatin 20 mg at bedtime,once a day+aspirin;methylprednisolone group was orally given methylprednisolone 0.8 mg/kg in the early morning,once a day+aspirin;combination group was given atorvastatin+methylprednisolone+aspirin(the same usage and dosage with the above-mentioned groups). The course was 4 weeks. The clinic data was observed,including ALT,AST, GGT,TB and DB before and after treatment,the incidence of patients with drug-induced liver disease and prognosis of patients with drug-induced liver disease. RESULTS:After treatment,the ALT,AST and GGT in atorvastatin group and combination group were significantly higher than before,with significant difference(P0.05). There was no significant dif-ference in the elevated rate of ALT among groups(P>0.05);the incidence of drug-induced liver disease in combination group was significantly higher than atorvastatin group and methylprednisolone group,with significant difference(P<0.05). ALT in combina-tion group was significantly decreased and returned to pretreatment levels after atorvastatin withdrawal and 2 weeks of hepatoprotec-tants treatment for 7 patients with drug-induced liver disease. CONCLUSIONS:Atorvastatin combined with methylprednisolone has high risk on liver function in the treatment of nephrotic syndrome. Pretreatment levels can be recovered by both drug withdrawal and symptomatic treatment.
ABSTRACT
Objective To evaluate the clinical efficacy of Dan-Hong Injection and Methycobal combined therapy in treating diabetic peripheral neuropathy(DPN).Methods 72 cases of peripheral neuropathy and type 2 diabetes(conformed to ADA standard published in 1999)were randomly separated into an experimem group and a control group.Members in the experiment group were treated with Dan-Hong injection 20ml/day i.v.and Methycobal 500ug/day i.m.Members in the control group were treated with Methycobal only.At the end of 2 weeks'therapeutic courses,motor nerve conducdon velocity (MNCV)and sural nerve conduction velocity(SNCV)were evaluated.Results The overall effective rate was 92.1% in the experiment group and 67.6% in the control group,showing significant difference between the two groups(P＜0.01).The post-therapeutic values of both SNCV and MNCV were significantly different from those of previous treatment.(P＜0.01)The post-therapeutic values of SNCV and MNCV of the experiment group were also significantly different from those of the control group(P＜0.05).No evidently relative adverse effects were observed in both groups.Conclusions Combined therapy of Dan-Hong injection and Methycobal was more effective in controlling the clinical activity of diabetic peripheral neuropathy.
ABSTRACT
Objective To evaluate the clinical efficacy of traditional Chinese mental intervention in treating post-apoplexy depressive disorder and its effects on recovery of activities of daily living(ADL).Methods 64 cases of post-apoplexy depressive disorder patients of light or moderate degree(evaluated by HAMD scale)were randomly separated into an experiment group and a control group.On the basis of identical basic clinical treatments,the experiment group was treated with traditional Chinese mental intervention,and the results were evaluated by HAMD scale and ADL scale at the 40th,the 70th and the 100th day.Results There were no differences in marks of the two scale between the experiment group and the control group at the beginning(P＞0.05).At the 40th day,the HAMD scale mark was 13.04±4.86 in the experiment group and 17.92±5.82 in the control group,showing significant differences(P＜0.05)between the two groups.At the same time,the ADL scale mark was 61.85±11.73 in the experiment group and 53.02±10.54 in the control group,showing significant differences between the two groups too(P＜0.05).At the 70th day and 100th day,the differences became much more notable(P＜0.01).Conclusion Traditional Chinese mental intervention was effective in promoting the motor function and activities of daily living and relieving the depress disorder for post-apoplexy depressive disorder.Post-apoplexy depress disorder patients should be treated with Chinese traditional mental intervention as soon as possible.
ABSTRACT
Objective To observe the clinical efficacy of incipient diabetic nephropathy treated with Ligustrazine Hydrechloride Injection plus Candesartan Cilexetil.Methods 80 cases of incipient diabetic nephropathy were randomly divided into a treatment group and a control group,with 40 cases in each group.On the basis of treated with insulin and antidiabetic drugs,The control group was given Candesartan Cilexetii and the treatment group was given Candesartan Cilexetil together with Ligustrazine Hydrochloride Injection.Results Plasma level of ET and NO,UAER and Ua1-MG of the two groups were all reduced,while the improvement of the treatment group was better than the control group.Conclusion The combination treatment of Ligustrazine Hydrochloride Injection and Candesartan Cilexetil was an ideal one for patients with incipient diabetic nephropathy.
ABSTRACT
Objective To evaluate the curative effect of integrated traditional Chinese and western medicine in treating diabetic nephropathy. Methods 114 cases of type 2 diabetes were randomly separated into experiment group and control group. Members in the experiment group were treated by integrated traditional Chinese and western medicine and Members in the control group were treated with western medicine alone for 8 weeks' course separately. At the end of therapeutic courses, levels of 24 h total proteinuria, serum creatinine, blood-fasting sugar were evaluated. Results In the experiment group, 8 cases got outstanding effects(11.1%), 50 cases got improvement(69.4%), and 14 cases got no effect (19.4%), with a total effective rate of 80.6%. In the control group, 0 cases got significant effect, 24 cases got improvement(33.3%), and 48 cases got no effect(66.7%), with a total effective rate of 33.3%. There was significant difference in total effective rate between the two groups (P＜0.05), that the total effective rate of the experiment group was significantly higher than that of the control group. Conclusion Integrated traditional Chinese and western medicine therapy can be more effective in treating diabetic nephropathy.